SLGL — Sol-Gel Technologies Ltd.

Is SLGL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of August 19, 2026

Sol-Gel Technologies Ltd. (SLGL) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $79.33. The rating moved from Oversold to Neutral on August 18, 2026.

AI analysis

Sol-Gel Technologies Ltd. (SLGL) sits in a thematic area that could benefit from a biologics/CRO/CDMO tailwind if the company can win commercial work tied to expanding mRNA/biologics production. Recent market rotation into growth names provides short-term support, but company-specific transparency is limited and makes assessment of financial health and runway difficult. The firm faces typical small-cap risks—low liquidity, execution and customer concentration—and competition from larger suppliers. Near-term catalysts would include disclosed revenue wins, partnership announcements, or clearer financial reporting; absent those, expect price action driven by broader sector flows and sentiment with elevated volatility.

Key factors

  • Exposure to biologics/CRO/CDMO demand expansion tied to positive mRNA/biologics data, which could provide meaningful revenue upside if Sol-Gel captures incremental fill/finish or materials demand
  • Recent market risk-on sentiment and rotation into growth/biotech names could support near-term share price momentum
  • Limited publicly-available recent filings and financial detail increase uncertainty around balance sheet strength and near-term cash runway
  • Small-cap / microcap characteristics: low liquidity and higher volatility relative to larger peers
  • Product / technology positioning and any niche intellectual property could be a differentiator, but clarity on commercial traction is lacking
  • Dependence on a few customers or contracts (typical for specialized suppliers) would concentrate revenue risk

Risks

  • Sparse recent corporate disclosure and no EDGAR comparables provided, creating visibility risk on revenues, margins, and cash runway
  • High competitive intensity from larger, better-capitalized CRO/CDMO and materials suppliers
  • Macroeconomic or geopolitical shocks could quickly reverse risk-on flows that have recently supported small biotech/tech names
  • Regulatory or quality compliance issues (FDA, supply-chain audits) that can materially interrupt customer relationships or shipments
  • Low daily trading volume causing price swings and complicating execution for larger orders
  • Execution risk on converting scientific/technical capability into scalable commercial contracts and predictable cash flows

See today's live rating, score and targets

Members see the live hourly rating for SLGL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.